ストックスクリーナーアプリを入手
14.72
0.81%
-0.12
前日終値:
$14.84
開ける：
$14.8
24時間の取引高:
1.64M
Relative Volume:
1.46
時価総額：
$1.23B
収益：
$7.62M
当期純損益:
$-271.60M
株価収益率:
-4.2036
EPS:
-3.5018
ネットキャッシュフロー:
$-271.54M
1週間 パフォーマンス:
+5.29%
1か月 パフォーマンス:
+19.38%
6か月 パフォーマンス:
-9.30%
1年 パフォーマンス:
+33.09%
1日の値動き範囲:
$13.89
$14.80
1週間の範囲:
$13.40
$14.99
52週間の値動き範囲:
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.72 | 1.23B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-07 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-22 | 開始されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Mizuho | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2021-01-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-06 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 再開されました | Laidlaw | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
すべてを表示
Eyepoint Inc (EYPT) 最新ニュース
Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st
ETFs Investing in EyePoint, Inc. Stocks - TradingView
EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - ad-hoc-news.de
EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo
EyePoint (EYPT) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Price to sales forward of EyePoint, Inc. – FWB:PV3B - TradingView
Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Insider Monkey
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901 - Ophthalmology Times Europe
Price to sales forward of EyePoint, Inc. – DUS:PV3B - TradingView
Price to earnings forward of EyePoint, Inc. – DUS:PV3B - TradingView
Guggenheim reiterates Buy on EyePoint stock, cites trial progress - Investing.com
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech - ad-hoc-news.de
EYPTEyePoint Inc Forecast, Target Price - Finviz
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com - Investing.com South Africa
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock - Investing.com
Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
EyePoint CMO sells 4,875 shares after option exercise | EYPT Insider Trading - Stock Titan
EYPT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Deceleration Risk - dars.gov.et
Spruce Street Capital LP's EyePoint Inc(EYPT) Holding History - GuruFocus
EYPT Rated Buy by Chardan Capital -- Price Target Raised to $65. - GuruFocus
Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile? - Sahm
Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating - marketscreener.com
Huge - Moomoo
Chardan Capital Maintains EyePoint(EYPT.US) With Buy Rating, Raises Target Price to $65 - Moomoo
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark - marketscreener.com
Pivotal Clinical Trial Readouts On The Horizon; Keeping An Eye On EyePoint? - RTTNews
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could - The Motley Fool
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 3000E Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
EyePoint, Inc. Actuals & Estimates (NASDAQ:EYPT) - TradingView
Price to book forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to book forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EYPT Forecast — Price Target — Prediction for 2027 - TradingView
EyePoint, Inc. Actuals & Estimates (DUS:PV3B) - TradingView
EYPT Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesGAAP Earnings Report - dars.gov.et
(EYPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Inc (EYPT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to earnings forward of EyePoint, Inc. – LS:A2QJRU - TradingView
A2QJRU Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
Guggenheim Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $68 - Moomoo
EYPT Reiterated by Guggenheim -- Price Target Maintained at $68. - GuruFocus
Mizuho reiterates EyePoint stock rating on competitor timeline shift By Investing.com - Investing.com South Africa
Eyepoint Inc (EYPT) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):